

PERSONAL INFORMATION

Jessica Menis



✉ jessica.menis@iov.veneto.it

Sex|female| Date of birth|16/12/1982| Nationality|Italian

WORK EXPERIENCE

March 2018- now

Medical Oncologist and University Researcher

Medical Oncology Unit 2
Veneto Institute of Oncology
Via Gattamelata 64, 35128 Padova, Italy

November 2016 – January 2018

Practicien Assistant Specialist

DITEP - Drug Development Department
Gustave Roussy Cancer Campus Grand Paris
114 Rue Edouard Vaillant, 94805 Villejuif Cedex, Francia

- Responsible of inward patients
- Referent of about 12 phase 1 trials

July 2014 – October 2016

Clinical Research Physician

Medical Department
EORTC Headquarters
83 avenue E. Mounier, 1200 Bruxelles, Belgio
Attività d'ideazione, sviluppo, conduzione ed analisi di studi clinici di fase 2 e 3 nelle neoplasie toraciche e del distretto cervico-facciale; coordinazione delle attività e promozione del gruppo di investigatori europei del gruppo di neoplasie toraciche e del distretto cervico-facciale dell'EORTC. Infine collaborazione nella scrittura e pubblicazione di risultati delle ricerche traslazionali e degli studi clinici condotti.

EDUCATION AND TRAINING

27-29 August 2014

Medical Fellow

3d ETOP Residential Workshop
Gdansk, Poland

18-24 June 2011

Medical Fellow

13th edition of ECCO-AACR-EORTC-ESMO Workshop 'Methods in Clinical Cancer Research'
Waldhaus Flims, Switzerland

March 2008 – March 2012

Graduation as Medical Oncologist

University of Udine (Udine, Italy)
Vote: 70 cum laude/70

Thesis " *The verify of the guidelines application in thoracic oncology: the ICP as a measure instrument*"

15 October 2007

Graduation as Medical Doctor

University of Udine (Udine, Italy)
 Votazione: 103/110
 Tesi di Laurea: "Amenorrhoea predictive factors in a group of breast cancer patients treated with adjuvant chemotherapy"
 July 2001 **High School Graduation**
 Liceo Scientifico G. Marinelli (Udine, Italy)
 Vote: 80/100

PERSONAL SKILLS

Mother tongue(s) Italian

Other language(s)	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	Fluent	Fluent	Fluent	Fluent	Fluent
	-				
German	Fluent	Fluent	Fluent	Fluent	Fluent
	Sehr gut – Goethe Institut				
French	Fluent	Fluent	Fluent	Fluent	Fluent
	B2.1 ALLIANCE FRANCAISE				

Communication skills Good communication skills both with patients and colleagues, either oncologists and not-oncologists. Good team working spirit.

Organisational / managerial skills Good organization and managerial skills mainly developed at EORTC Headquarters as Clinical research Physician.

Clinical activity

Curriculum Vitae Replace with First name(s) Surname(s)

From March 2008 to March 2012 I worked as Specialist Registrar at the Department of Medical Oncology of the University Hospital in Udine, Italy. Under the supervision of a medical oncology specialist, I gained experience in the management of patients with a wide range of adult solid cancers in the in-patient and out-patient setting. My main clinical interest is lung cancer.

My job plan included:

- Out-patient duties:
 - lung cancer clinic, with follow-up visits (about 8 patients weekly)
 - newly diagnosed lung cancer patients (about 4 patients weekly)
 - a general (all other solid tumours) clinic, with follow-up visits (about 10 patients weekly) and newly diagnosed cancer patients (about 1 patient weekly)
 - a weekly chemotherapy clinic, mostly for patients with lung cancer
 - a general chemotherapy clinic (twice monthly)
 - a three time monthly toxicity clinic for patients who present with chemotherapy related toxicity

- In-patient duties:
 - One month a year I was responsible for the daily management of patients on the ward, under the supervision of a medical oncology specialist
 - I contributed to the registrar rota at the Medical Oncology Ward in Udine (night shift)

Once a week, I attended the lung cancer multidisciplinary team meeting where I was also responsible for keeping record of the cases being discussed and the panel decision in a dedicated database.

From May 2010 until February 2011 I worked as Visiting Clinical Research Fellow at St James's Teaching Hospital. I was attending the Oncological Meetings and Seminars and the Head & Neck Outpatient Clinic and Ward Round, the Head & Neck and Lung Multi Disciplinary Team (MDT) meetings, the Phase I Clinic and various seminars and Audit meetings held there weekly.

After my specialization I started a four months Fellowship at the Thoracic Unit of the University Hospital San Luigi Gonzaga in Orbassano (Turin, Italy) where I worked in the in-patient unit, focusing on lung cancer patients diagnosis and treatment.

There I had the opportunity to work also in the Radiology, Pathology and Radiotherapy Department thus widening my knowledge on the whole lung cancer patient management.

Since November 2016 I have been resident at DITEP in Gustave Roussy Cancer Campus Grand Paris where I am responsible of the hospitalized patients as well as of the trainees that are working there. All hospitalized patients are enrolled in the phase I trials currently active.

Clinical research

My main research interest has been lung cancer. Overall, during my training as a medical oncologist I have been co-investigator for 14 clinical trials in lung cancer at the University Hospital in Udine, including pharmaceutical company sponsored and investigator-lead phase II and phase III trials. I also attended two national workshops on clinical trial methodology.

Moreover, in June 2011 I attended the 13th edition of the ECCO-AACR-EORTC-ESMO Workshop 'Methods in Clinical Cancer Research' led in FLIMS where, by means of the lessons and active discussions with some of the world main experts on clinical trials, I developed a clinical trial protocol on Small Cell Lung Cancer.

From 1st October 2012 until I have started a Fellowship at the EORTC Headquarters (Brussels, Belgium). The main objective of this Fellowship has been to acquire a specific knowledge about cancer clinical trials, from both a scientific and an operational perspective. From October 1st 2012 to April 1st 2014 I have been assigned first, to the EORTC Head & Neck Cancer Group (HNCG) and thereafter, to the EORTC Lung Cancer Group (LCG) under the supervision of Dr. Denis Lacombe (Director of the Headquarters and Fellowship Program Coordinator) and Dr Ravi Karra (Clinical Research Physician of the HNCG, melanoma group and Pharmaco-vigilance Clinical Research Physician).

During this Fellowship, I have been working on several scientific activities included preparing protocol, Early Project Optimization Department (EPOD) forms, medical review plans, writing protocol outlines, submitting outlines to Protocol Review Committee (PRC), addressing PRC comments, writing grant applications.

These activities I have continued as Clinical research Physician of the EORTC Lung Cancer Group and Head and Neck Cancer Group from July 2014 until October 2016.

I also attended a number of training sessions and educational events, inside and outside the EORTC Headquarters. In particular I attended several seminars and a meetings on Lung Cancer and a meeting on both Head & Neck and Lung Cancer.

Translational research

From May 2010 until February 2011 I have been a Visiting Clinical Research Fellow in the Precancer Genomics Group (Supervisor Prof. Pamela Rabbitts) at the Section of Experimental Therapeutics, Page3 / 16

© Leeds Institute of Molecular Medicine (LIMM), University of Leeds.

I have been working, under supervision, on a granted project about the identification of new prognostic factors in lung cancer. I have gained experience in Immunohistochemistry scoring, DNA preparation, analysis and quality assessment.

Digital skills

SELF-ASSESSMENT				
Information processing	Communication	Content creation	Safety	Problem solving
Enter level	Enter level	Enter level	Enter level	Enter level

Levels: Basic user - Independent user - Proficient user
[Digital competences - Self-assessment grid](#)

 Driving licence
 Pubblicazioni

B

PRESENTAZIONI

- 3- 5Febbraio 2015
3d Symposium on thoracic and upper aerodygestivemalignancies (Atene, Grecia)
Ruolo: Invited Speaker
- 14 Gennaio 2016
EMA scientific advisory meeting (Londra, United Kingdom)
Ruolo: Invited Advisor
- 18- 24 Febbraio 2016
EMA - CDDF Joint Meeting on the Challenges for the Approval of Anti-Cancer Immunotherapeutic Drugs (Londra, United Kingdom)
Ruolo: Invited Speaker
- Jun 18- 24, 2016
Joint ECCO-AACR-EORTC-ESMO Workshop on Methods in Clinical Cancer Research
Methods in Clinical Cancer Research (Zeist, Netherlands)
Ruolo: Invited Faculty
- 06- 09Aprile 2017
4th Symposium on thoracic and upper aerodygestivemalignancies (Atene, Grecia)
Ruolo: Invited Speaker
- 15-19 Settembre 2018
ERS conference (Parigi, Francia)
Ruolo: Invited Speaker
- 11 Ottobre 2018
Translational medicine in lung cancer: from promises to progress (Padova, Italia)
Ruolo: Invited Speaker
- 12-13 Ottobre 2018
ONCOPROMises: educational program to improve skill efficiency in oncology (Roma, Italia)
Ruolo: Invited Speaker

CONFERENZE E SEMINARI

1. **17 Gen 2006 - Seminario** “Le cure palliative” (Udine, Italia)
2. **20-21 Dic, 2006 - Congresso** Focus sul carcinoma mammario: aggiornamenti basati sull'evidenza (Castello di Aviano (PN), Italia)
3. **16 Nov 2007- Convegno**Meet the Professor “Nuove acquisizioni nel trattamento adiuvante del carcinoma mammario” (Udine, Italia)

Presentazioni
 Progetti
 Conferenze
 Seminari
 Riconoscimenti e premi
 Appartenenza a gruppi /
 associazioni
 Referenze
 Menzioni
 Corsi
 Certificazioni

4. **28 Nov 2007 – Convegno** La gestione del paziente oncologico nell’Ospedale di San Daniele del Friuli (San Daniele del Friuli (Ud), Italia)
5. **24 – 25 Gen, 2008 - Convegno** Focus sul carcinoma mammario: aggiornamenti basati sull’evidenza V edizione (Udine, Italia)
6. **14 Mar 2008 - Convegno** Workshop e-oncology Informatica in Oncologia medica: stato dell’arte e prospettive (Udine, Italia)
7. **28 Mar 2008 - Convegno** “Ricerca e qualità di cura nel paziente con dolore cronico oncologico” (Udine, Italia)
8. **8 Mag 2008 - Attività formativa formazione residenziale** Campagna OMS-CCM “Clean Care is Safer Care” sull’igiene delle mani (Udine, Italia)
9. **8 Mag 2008 - Corso di aggiornamento** “Nuovi approcci terapeutici nel carcinoma mammario Erb-b2 positivo” (Udine, Italia)
10. **23 Mag 2008 – Convegno** Docetaxel in prima linea nel NSCLC avanzato: confronto aperto tra esperienze e opinioni (Udine, Italia)
11. **12 Giu 2008 - Convegno** Take-home Messages from ASCO (Udine, Italia)
12. **26 - 28 Giu, 2008 – Conferenza** 1° Conferenza italiana di Oncologia Toracica (Napoli, Italia)
13. **06 Ott, 10-24 Nov 2008 – Convegno** Meeting in Oncologia (Udine, Italia)
14. **7 Nov 2008 - Convegno** Focus sulle neoplasie ginecologiche: Le neoplasie del corpo dell’utero (Udine, Italia)
15. **17 Gen 2009 – Convegno** La monoterapia orale approvata per il trattamento del microcitoma recidivante (Verona, Italia)
16. **22 – 23 Gen, 2009 – Convegno** Focus sul carcinoma mammario: aggiornamenti basati sull’evidenza VI edizione (Pordenone, Italia)
17. **12– 13 Feb, 2009 - Convegno** Convegno interregionale AIOM “La multidisciplinarietà in oncologia” (Mogliano Veneto (TV), Italia)
18. **25 – 26 Feb, 2009 Investigator Meeting** CASA404A2302 Investigator Meeting (Francoforte, Germania)
19. **20– 21 Mar, 2009 Corso** La donna con carcinoma mammario: dalle novità della ricerca alla pratica clinica (Camogli (GE), Italia)
20. **17 Apr 2009 - Convegno** “Onco-Endo-Net FVG 2009” (San Daniele del Friuli (Ud), Italia)
21. **22 Mag 2009 – Convegno** Carcinomi avanzati della Testa e Collo (Aviano (PN), Italia)
22. **05 Giu 2009 – Convegno** “ToGetErb – La nuova opzione terapeutica nel carcinoma mammario ErbB2+” (Udine, Italia)
23. **15 Giu 2009 - Evento formativo** Anticorpi monoclonali nella neoplasia del colon-retto: innovazione tra presente e futuro (Mortegliano (UD), Italia)
24. **19 – 20 Giu, 2009 - Corso Educazionale** V Corso Educazionale Giovani Oncologi

- AIOM "Trattamenti neo-adiuvanti nel tumore gastrico, rettale e mamario: a chi, come, quando e perché" (Roma, Italia)
25. **10 Lug 2009 – Convegno** "Focus sul carcinoma coloretale 2009" (Udine, Italia)
 26. **10 – 13 Ott, 2009 – Congresso** XI Congresso nazionale in Oncologia medica (Milano, Italia)
 27. **22 – 23 Ott, 2009 – Convegno** 6th ATOM – Alpe Adria Thoracic Oncology Multidisciplinary group "Innovazione nel trattamento del tumore polmonare percorsi clinici, agenti biologici e terapie "personalizzate" (Udine, Italia)
 28. **29 Ott 2009 – Convegno** "The effect of Tyrosine Kinase Inhibitors on Breast Cancer Stem Cells" (Udine, Italia)
 29. **30 – 31 Ott, 2009 – Congresso** 1st Workshop di Endocrinologia Oncologica: innovazioni in tema di terapia" (Udine, Italia)
 30. **13 Nov 2009 – Convegno** Profilassi e terapia del tromboembolismo venoso: "L'esperto risponde" (Udine, Italia)
 31. **27 – 28 Nov, 2009 - Corso Nazionale** Bersaglio Polmone Nuovi orizzonti diagnostico-terapeutici in oncologia polmonare (Orbassano (TO), Italia)
 32. **22 Gen 2010 - Corso di aggiornamento** Corso Itinerante Nazionale AIORadio-Chemioterapia nel NSCLC localmente avanzato (Torino, Italia)
 33. **26 Gen 2010 – Corso** "Primi passi in caso di emergenza" (Udine, Italia)
 34. **19 Mar 2010 – Conferenza** From histology to molecular biology: clinical and therapeutic implications in non small cell lung cancer (Trento, Italia)
 35. **09 – 10 Lug, 2010 – Convegno** 2010 News in Oncology Convegno nazionale AIOM giovani oncologi (Brufa di Torgiano (PG), Italia)
 36. **07 – 10 Nov, 2010 – Conferenza** NCRI Cancer Conference (Liverpool, Gran Bretagna)
 37. **07 Mar, 2011 – Corso** Emergenza da adottare in caso di incendio nella struttura operativa (Udine, Italia)
 38. **09 Giu, 2011 – Convegno** Terapia ormonale del carcinoma mammario (Udine, Italia)
 39. **01 – 02 Lug, 2010 – Convegno** "2011 News in Oncology" Convegno nazionale AIOM giovani oncologi (Brufa di Torgiano (PG), Italia)
 40. **22 Ott, 2011 – Convegno** LUNG11 Post-Amsterdam (Sondalo (SO), Italia)
 41. **04 Nov, 2011 – Convegno** "Sessione educativa AIOM giovani oncologi" Congresso nazionale AIOM 2011 (Bologna, Italia)
 42. **05 – 07 Nov, 2011 – Congresso** XIII Congresso nazionale di Oncologia medica (Bologna, Italia)
 43. **20 – 21 Gen, 2012 - Corso Nazionale** Bersaglio Polmone – 3° corso nazionale "Nuovi orizzonti diagnostico-terapeutici in oncologia polmonare" (Bari, Italia)
 44. **26 – 27 Gen, 2012 – Congresso** Focus sul carcinoma mammario: aggiornamenti

basati sull'evidenza IX edizione (Tavagnacco (Ud), Italia)

45. **17 Feb 2012 - Convegno Internazionale** 'Amianto, lo Stato dell'arte. Salute e Ambiente' (Udine, Italia)
46. **2 Mar 2012 – Convegno** Sostenibilità del sistema sanitario pubblico: quali prospettive? (Udine, Italia)
47. **8 Mar 2012 - Seminario** La tipizzazione cito-istologica dei NSCLC in funzione della target therapy (Udine, Italia)
48. **19 Mar 2012 – Convegno** Profile “La terapia antiangiogenica nel tumore della mammella: esperienze a confronto (Aviano (PN), Italia)
49. **20 – 22 Apr, 2012 – Conferenza** XX conferenza nazionale AIOM (Mestre (VE), Italia)
50. **23 Mag 2012 – Convegno** Trattamento adiuvante del carcinoma mammario – meet the expert (Torino, Italia)
51. **25 Mag 2012 – Convegno** Il carcinoma del polmone: il parere degli specialisti attraverso i casi clinici (Moncalieri (TO), Italia)
52. **20 – 21 Giu Padova, 2012- Conferenza** MiThO (Padova, Italia)
53. **22 Giu 2012 – Convegno** Controversie nel trattamento del MCRC (Udine, Italia)
54. **06 – 07 Lug, 2012 – Convegno** 2012 News in Oncology Convegno nazionale AIOM giovani oncologi (Brufa di Torgiano (PG), Italia)
55. **20 Set 2012 – Convegno** La terapia personalizzata nel NSCLC: un approccio multidisciplinare (Trieste, Italia)
56. **09 Nov, 2012 – Seminario** Meet the oncology expert – “Measurement and prediction of pathological response as a surrogate for survival” (Bruxelles, Belgio)
57. **23 – 24 Nov, 2012 – Convegno** Gene profiling in clinical oncology course (Viareggio, Italia)
58. **11 – 14 Dec, 2012 – Conferenza** Methodology of cancer clinical trials: the next generation” (Bruxelles, Belgio)
59. **19 Gen, 2013 – Conferenza** 9th pan-d symposium on thoracic oncology (Ghent, Belgio)
60. **01 Feb, 2013 – Seminario** Meet the oncology expert – “New frontiers in endocrine therapy for breast cancer and biology from whole genome sequencing” (Bruxelles, Belgio)
61. **14-15 Mar, 2013 – Conferenza** 2013 lung cancer conference (Luxembourg, Luxembourg)
62. **04 – 06 Apr, 2013 – Conferenza** 2nd symposium on thoracic and upper aerodigestive malignancies (Atene, Grecia)
63. **19 Apr, 2013 – Seminario** Meet the oncology expert – “The continuum of care for patients with metastatic colorectal cancer – is there a preferred strategy?” (Bruxelles, Belgio)

64. **24 Mag, 2013 – Seminario** Meet the oncology expert – “Tumor heterogeneity: causes” (Bruxelles, Belgio)
65. **11 – 14 Jun, 2013 – Corso** Clinical trial statistics for non statisticians (Bruxelles, Belgio)
66. **25 – 29 Sett, 2013 – Conferenza** 17th ECOO-38th ESMO European Cancer Congress(Amsterdam, Olanda)
67. **11 Oct, 2013 – Seminario** Meet the oncology expert – “Molecular imaging in oncology: current status and future prospects” (Bruxelles, Belgio)
68. **5-6 Nov, 2013 – Conferenza** Diagnostic development tutorial “from hypothesis to product” (Bruxelles, Belgio)
69. **7-9 Nov, 2013 – Conferenza** Markers in cancer: a joint meeting by ASCO, EORTC and NCI (Bruxelles, Belgio)
70. **16 Nov, 2013 - Conferenza** Update in respiratory oncology (Bruxelles, Belgio)
71. **27 - 28 Nov, 2013 – Conferenza** Post-IASLC: updates da Sidney (Lucca, Italia)
72. **10 Gen, 2014 – Seminario** Meet the oncology expert – “We will cure melanoma: the current revolution” (Bruxelles, Belgio)
73. **18 Gen, 2014 – Conferenza** 10th thoracic oncology winter symposium (Ghent, Belgio)
74. **31 Gen – 1 Feb, 2014 – Conferenza** 3d lung cancer network “From the bench to the bedside” (Atene, Grecia)
75. **14 Mar, 2014 – Conferenza** Meet the oncology expert – “Bench to bedside in lung cancer research” (Bruxelles, Belgio)
76. **26 – 29 Mar, 2014 – Conferenza** 4th european lung cancer conference – ELCC (Ginevra, Svizzera)
77. **21 Giugn, 2014 – Conferenza** PostASCO meeting (Genval, Belgio)
78. **13Set, 2013 - Corso**One day introduction to EORTC trials (Bruxelles, Belgio)
79. **26 – 30 Sett, 2014 – Conferenza** 39th ESMO Congress (Madrid, Spagna)
80. **29 Nov, 2014 – Conferenza** Eight belgian symposium on the integration of molecular biology advances into oncology clinical practice (Bruxelles, Belgio)
81. **05 – 07 Feb, 2015 – Conferenza** 3d symposium on thoracic and upper aerodigestive malignancies (Atene, Grecia)
82. **15 – 18 Apr, 2015 – Conferenza** 5th european lung cancer conference – ELCC (Ginevra, Svizzera)
83. **06 – 09 Sett, 2015 – Conferenza** World Lung Cancer Conference (Denver, USA)
84. **25 – 29 Sett, 2015 – Conferenza** 18th ECOO-40th ESMO European Cancer Congress (Vienna, Austria)
85. **23 – 24 Ott, 2015 – Conferenza** MAPS – molecular analysis for personalized therapy (Parigi, Francia)
86. **4 – 5 Feb, 2016 – Conferenza** EMA-CDDF joint meeting “Challenges for the

- approval of anticancer immunotherapeutic drugs (Londra, United Kingdom)
87. **13 – 16 Apr, 2016 – Conferenza** 6th european lung cancer conference – ELCC (Ginevra, Svizzera)
88. **8 Nov, 2016 – Conferenza** CLIP-Lille (Lille, France)
89. **13 Gen, 2017 – Conferenza** Best of WCLC 2016 – Paris (Parigi, France)
90. **06 – 09 Apr, 2017 – Conferenza** 4th symposium on thoracic and upper aerodigestive malignancies (Atene, Grecia)

RICONOSCIMENTI E PREMI

- Premio della Fondazione AIOM per la borsa di studio “Strategie diagnostiche ed approcci terapeutici al tumore polmonare”
- Premio della Fondazione AIOM per la borsa di studio “Carcinoma del Polmone”
- Premio della Fondazione AIOT per la borsa di studio “Le neoplasie toraco-polmonari”

SOCIETIES MEMBERSHIP

- American Association for Cancer Research (AACR) 2011
- Flims Alumni Club since 2011
- European Society of Medical Oncology (ESMO) since 2009
- Associazione Italiana di Oncologia Medica (AIOM) since 2008
- Associazione Italiana di Oncologia Toracica (AIOT) since 2009
- Women Against Lung Cancer in Europe (WALCE) since 2010
- Alpe-Adria Thoracic Oncology Multidisciplinary group (ATOM) since 2008
- European Organization for research and treatment of cancer (EORTC) Lung cancer group, head and neck cancer group and elderly task force since 2016

ABSTRACTS

1. Minisini A.M, **Menis J**, Valent F, Andreetta C, Alessi B, Pascoletti G, Piga A, Fasola G, Puglisi F.
Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era
American Society of Clinical Oncology Annual Meeting 2008, Chicago (poster)
2. Aita M, Giacomuzzi F, Lirusso E, Rizzato S, Rijavec E, Merlo V, **Menis J**, Geatti O, Fasola G
Diagnostic and prognostic value and staging performance of dual time point 18F-FDG/CT imaging in malignant pleural mesothelioma (MPM)
ESMO Meeting 2008 (poster)
3. Aita M, Zanier L, Rijavec E, Merlo V, **Menis J**, Della Mea V, Deroma L, Donato R, Puglisi F, Fasola G.
Toward incident reporting (IR) systems: a safety culture survey within the oncology network of a Northern Italian region
American Society of Clinical Oncology Annual Meeting 2009, Orlando (poster)
4. Aita M, Zanier L, Rijavec E, Merlo V, **Menis J**, Della Mea V, Deroma L, Donato R, Puglisi F, Fasola G
Attitudes and barriers to incident reporting in oncology: evidence from a safety culture survey within a regional cancer network
ESMO Meeting 2009 (poster)

5. Rijavec E, Merlo V, Aita M, **Menis J**, Sibau A, Follador A, Beer Z, Gaiardo M, Fasola G
Curative surgery in oligometastatic non-small cell lung cancer patients
AIOM Meeting 2009 (poster)
6. Merlo V, Rijavec E, Aita M, **Menis J**, Rizzato S, Rossetto C, Beer Z, Gaiardo M, Fasola G
Curative surgery in oligometastatic non-small cell lung cancer patients
ESMO Meeting 2009 (poster)
7. Aita M, Belvedere O, De Pauli F, Deroma L, Gurrieri L, **Menis J**, Merlo V, Puglisi F, Zanier L, Fasola G
Information technology (IT) and chemotherapy (CT) prescribing errors
American Society of Clinical Oncology Annual Meeting 2010, Chicago (poster)
8. Rizzato S, Gaiardo M, Giacomuzzi F, Lugatti E, Meduri S, **Menis J**, Merlo V, Sibau AM, Tozzi V, Fasola G
Integrated care pathways (ICPs) for non-small cell lung cancer (NSCLC) patients (Pts): A multidisciplinary quality improvement project.
ESMO Meeting 2010 (poster)
9. Aita M, De Carlo E, De Pauli F, Gurrieri L, Deroma L, Follador A, Mansutti M, **Menis J**, Merlo V, Puglisi F, Zanier L, Fasola G
Chemotherapy (CT) prescription errors: which role for computerized physician order entry (CPOE) systems and information technology?
AIOM Meeting 2010 (oral communication)
10. Rizzato S, Merlo V, Gurrieri L, **Menis J**, Follador A, Toscani P, Zumerle G, Guarrera GM, Fasola G
Integrated care pathways (ICPs) for non-small cell lung cancer (NSCLC) patients (Pts): A multidisciplinary quality improvement project.
SIAPEC-IAP National Meeting 2010 (poster)
11. Rizzato S, Merlo V, Aita M, Sibau A, **Menis J**, Gurrieri L, Lugatti E, Gaiardo M, Meduri S, Giacomuzzi F, Tozzi V, Fasola G
Integrated care pathways (ICPs) for non-small cell lung cancer (NSCLC) patients (Pts): A multidisciplinary quality improvement project.
American Society of Clinical Oncology Annual Meeting 2011, Chicago (poster)
12. Tcherveniakov P, Belvedere O, **Menis J**, Wood H, Berri S, Milton R, Papagiannopoulos K, Rabbits P
Genomic Biomarkers of Progression in Patients with Stage I NSCLC
19th European Conference on General Thoracic Surgery 2011 (poster)
13. De Maglio G, Fasola G, Sibau A, Iop A, Rizzi C, Del Conte A, Sulfaro S, Adami G, Vigevani E, de Pangher Manzini V, Brollo A, Colonna A, Cemic S, Masiero E, **Menis J**, Pizzolitto S
EGFR testing in NSCLC: the first year of experience
SIAPEC-IAP National Meeting 2011 (poster)
14. Bin A, Dipace R, Pagnutti L, **Menis J**, Fasola G, Donato R
Utilizzo degli infrarossi per la visualizzazione dei vasi periferici
SIHTA 4th National Meeting 2011 (poster)
15. Merlo V, Rizzato S, Sibau AM, Zumerle G, Gaiardo M, Gurrieri L, Macerelli M, **Menis J**, Tozzi V, Fasola G
Integrated care pathways (ICPs) for non-small cell lung cancer (NSCLC) patients (Pts):

- Avoidable cost analysis in a quality improvement project.*
AIOM Meeting 2011 (poster)
16. **Menis J**, Follador A, Valent F, Rizzato S, Merlo V, Gurrieri L, Macerelli M, De Carlo E, Gaiardo M, De Maglio G, Parisi G, Lugatti E, Giacomuzzi F, Tozzi V, Fasola G
Integrated care pathways in lung cancer: a quality improvement project
3rd International Conference on Thoracic Oncology, Naples 2012 (poster)
17. Lutrino ES, Casagrande M, **Menis J**, Ferrari L, De Maglio G, Foltran L, Mazzer M, Cardellino GG, Iaiza E, Giovannoni M, Pella N, Pizzolitto S, Aprile G.
Brain metastases (BM) biology in long-term survivors of advanced colorectal cancer (CRC)
IV European Conference on survivors and chronic cancer patients: evidence and operative directions. Siracusa 2012 (poster)
18. **Menis J**, Follador A, Valent F, Rossetto C, Gaiardo M, Gurrieri L, Lugatti E, Pizzolitto S, Tozzi V, Fasola G
Quality indicators and Non Small Cell Lung Cancer Integrated Care Pathway: a single-center experience
Accepted at 37th ESMO Congress (abstract)
19. Capelletto E, Novello S, Solitro F, Focaraccio L, Giaj Levra M, Rapetti SG, Vavala T, Menis J, Veltri A, Scagliotti GV.
Retrospective study of radiological findings of pulmonary embolism (PE) in patients (pts) with advanced non small cell lung cancer (NSCLC)
Accepted at 37th ESMO Congress (abstract)
20. **Menis J**, Follador A, Valent F, Merlo V, Sibau A, Gaiardo M, Macerelli M, De Carlo E, Ceschia T, Parisi G, Giacomuzzi F, Tozzi V, Pacileo G, Fasola G
Quality indicators and non small cell lung cancer integrated care pathway: a single-center experience
Accepted at XIV AIOM Meeting (abstract)
21. Follador A, **Menis J**, Valent F, Merlo V, Gardenal N, De Carlo E, De Maglio G, Fasola G
Analisi retrospettiva di indicatori di qualità nel percorso diagnostico terapeutico (PDTA) del tumore polmonare non a piccole cellule
SIHTA National Meeting 2012 (poster)
22. Novello S, Follador A, Morabito A, Giaj Levra M, **Menis J**, Bria E, Martelli O, Galetta D, Spitaleri G, Caffo O, Tiseo M, Cecere F, Rijavec E, Zilembo N, Banna G, Rossi A.
BE-Positive: Gefitinib in first-line treatment of advanced non-small cell lung cancer (NSCLC) patients harboring activating epidermal growth factor receptor (EGFR) mutations. A combined retrospective and prospective analysis from Italian patients.
Accepted at WCLC 2013 (poster)
23. O'Brien M, Gaafar R, Hasan B, **Menis J**, Cufer T, Popat S, Woll P, Surmont V, Georgoulas V, Montes A, Blackhall F, Hennig I, Schmid-Bindert L, Baas P
Double blind randomized phase III study of maintenance Pazopanib® (Pz) versus placebo (P) in non small cell lung cancer (NSCLC) patients (pts) non progressive after first line chemotherapy [CT] (EORTC Lung Cancer Group, 08092): MAPPING
Accepted ESMO 2014 (poster)
24. Besse B, **Menis J**, Adam J, Dziadziuszko R, Hasan B, Lacroix L, Peters S, Lacombe D, O'Brien M, Stahel R

- SPECTALung Screening Patients with thoracic malignancies for Efficient Clinical Trial Access*
Accepted ELCC 2015 (poster)
25. **Menis J**, BesseB, AdamJ, Dziadziuszko R, Lacroix L, PetersS, HasanB, SteuveJ, SzepessyE, VarinE, GolfopoulosV, StahelR
SPECTALung Screening Patients with thoracic malignancies for Efficient Clinical Trial Access
Accepted WIN symposium 2015 (poster)
26. **Menis J**, Girard N, Hasan B, Besse B
Pan-European survey on thymic malignancies: A collaboration of the EORTC Lung Cancer Group (LCG) with the RYTHMIC network
Accepted at WCLC 2015 (poster)
27. BesseB, **MenisJ**, AdamJ, BerghmansT, CuferT, DziadziuszkoR, FilipE, FinnSP, LacroixL, MazièresJ, MelgaardP, NovelloS, PetersS, PopatS, ReckM, SmitE, VansteenkisteJ, HasanB, SteuveJ, VarinE, LacombeD, StahelR
SPECTALung Screening Patients with thoracic malignancies for Efficient Clinical Trial Access
Accepted WCLC 2015 (poster)
28. **Menis J**, Girard N, Hasan B, Besse B
Pan-European survey on thymic malignancies: A collaboration of the EORTC Lung Cancer Group (LCG) with the RYTHMIC network
Accepted at ECCO-ESMO 2015 (poster and ESMO spotlight presentation)
29. **Menis J**, Ammari S, Dyevre V, Paoletti X, Levy A, Massard C, Soria JC, Marabelle A, Even C, Pautier P, Hollebecque A, Deutsch E
Evaluation of the response to immunotherapy agents in previously irradiated fields
Accepted at TAT 2017 (poster)

FULL PAPERS

1. Minisini AM, **Menis J**, Valent F, Andreetta C, Alessi B, Pascoletti G, Piga A, Fasola G, Puglisi F.
Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era
Anticancer Drugs 2009; 20: 503-07
2. Della Mea V, De Momi I, Aprile G, Puglisi F, **Menis J**, Casetta A, Bolzonello S, Fasola G.
Feasibility study of a web application for self-report of anticancer treatment toxicities.
Stud Health Technol Inform. 2009;150:562-566
3. Follador A, **Menis J**, Sacco C
Approccio multidisciplinare a una neoplasia neuroendocrina atipica di origine polmonare
ClinicalCasesfor the Lanreotide Award in Neuroendocrine Tumours
Supplement of the Journal "Casi Clinici in Oncologia"
4. **Menis J.**
Tumore polmonare a piccole cellule (SCLC-Small Cell Lung Cancer) o Microcitoma polmonare.
http://www.womenagainstlungcancer.eu/public/Tumore_polmonare_a_piccole_cellule.pdf

5. Banna GL, Di Maio M, Follador A, Collovà E, **Menis J**, Novello S, Bria E & ISA Co-Authors
Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)
Lung Cancer. 2011;73(1):78-88
6. Minisini AM, **Menis J**, Follador A, Avellini C, Fasola G
Fulminating septic shock from Clostridium Perfringens in an early breast cancer patient with severe myalgia after docetaxel treatment: a case report and mini-review of the literature
Clinics and Practice 2011; volume 1:e33
7. **Menis J**, Twelves C
Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer
Breast Cancer: Targets and Therapy 2011;3 101–111
8. Belvedere O, Berri S, Chalkley R, Conway C, Barbone F, Pisa F, MacLennan K, Daly C, Alsop M, Morgan J, **Menis J**, Tcherveniakov P, Papagiannopoulos K, Rabbitts P, Wood HM.
A computational index derived from whole-genome copy number analysis is a novel tool for prognosis in early stage lung squamous cell carcinoma.
Genomics. 2012; 99(1):18-24
9. **Menis J**, Fontanella C, Follador A, Fasola G, Aprile G.
Brain metastases from gastrointestinal tumours: Tailoring the approach to maximize the outcome.
Crit Rev Oncol Hematol. 2013; 85(1):32-44
10. Aprile G, De Maglio G, **Menis J**, Casagrande M, Tuniz F, Pisa EF, Fontanella C, Skrap M, Beltrami AC, Fasola G, Pizzolitto S.
HER-2 Expression in Brain Metastases from Colorectal Cancer and Corresponding Primary Tumors: A Case Cohort Series.
Int J Mol Sci. 2013;14(2):2370-87
11. **Menis J**, Giaj Levra M, Novello S.
MET inhibition in lung cancer
Translational Lung Cancer Research 2013; 2(1): 23-39
12. Hasan B, Greillier L, Pallis A, **Menis J**, Gaafar R, Sylvester R, Fennell DA, Baas P, Surmont V, Van Meerbeeck JP, O'Brien ME
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation.
Eur J Cancer. 2014;50(16):2771-82
13. **Menis J**, Hasan B, Besse B.
New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response.
Eur Respir Rev. 2014;23(133):367-78
14. O'Brien ME, Gaafar R, Hasan B, **Menis J**, Cufer T, Popat S, Woll PJ, Surmont V, Georgoulas V, Montes A, Blackhall F, Hennig I, Schmid-Bindert G, Baas P; EORTC-LCG
Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT:

2010-018566-23, NCT01208064).
Eur J Cancer. 2015;51(12):1511-28

15. **Menis J**, Besse B, Lacombe D.
Methodology of clinical trials in lung cancer.
Chin Clin Oncol. 2015;4(4):44
16. Abdelraouf F, Smit E, Hasan B, **Menis J**, Popat S, van Meerbeeck JP, Surmont VF, Baas P, O'Brien M.
Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061).
Eur J Cancer. 2016; 54:35-9
17. Vavalà T, Follador A, Tiseo M, Galetta D, Morabito A, Di Maio M, Martelli O, Caffo O, Piovano PL, Cortinovis D, Zilembo N, Casartelli C, Banna GL, Ardizzoia A, Barzelloni ML, Bearz A, Genestreti G, Mucciarini C, Filipazzi V, **Menis J**, Rizzo E, Barbieri F, Rijavec E, Cecere F, Bria E, Spitaleri G, Rossi A, Novello S.
BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR-positive non small cell lung cancer patients: Results from a multicenter Italian observational study.
Lung Cancer. 2016; 95:73-81
18. Henriques De Figueiredo B, Fortpied C, **Menis J**, Lefebvre JL, Barzan L, de Raucourt D, Geoffrois L, Giurgea L, Hupperets P, Leemans CR, Licitra L, Rolland F, Tesselaar M, Vermorken JB, Grégoire V; EORTC Head and Neck Cancer and Radiation Oncology Cooperative Groups.
Long-term update of the 24954 EORTC phase III trial on larynx preservation.
Eur J Cancer. 2016; 65:109-12
19. **Menis J**, Litiere S, Tryfonidis K, Golfinopoulos V.
The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics.
Ann Transl Med 2016; 4(14):267
20. Remon J, **Menis J**, Hasan B, Peric A, De Maio E, Novello S, Reck M, Berghmans T, Wasag B, Besse B, Dziadziuszko R.
The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613.
Clin Lung Cancer. 2017 Mar 1. pii: S1525-7304(17)30048-7
21. Pilotto S, Rossi A, Vavalà T, Follador A, Tiseo M, Galetta D, Morabito A, Di Maio M, Martelli O, Caffo O, Piovano PL, Cortinovis D, Zilembo N, Casartelli C, Banna GL, Ardizzoia A, Barzelloni ML, Bearz A, Genestreti G, Mucciarini C, Filipazzi V, **Menis J**, Rizzo E, Barbieri F, Rijavec E, Cecere F, Spitaleri G, Bria E, Novello S.
Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study.
Clin Lung Cancer. 2017 Jun 1. Epub ahead of print
22. Psyri A, Fortpied C, Koutsodontis G, Avgeris M, Kroupis C, Goutas N, **Menis J**, Herman L, Giurgea L, Remenar E, Degardin M, Pateras IS, Langendijk JA, van Herpen C, Awada A, Germà-Lluch JR, Kienzer HR, Licitra L, Vermorken JB.
Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: A subset

- analysis of EORTC 24971 study.*
Ann Oncol. 2017 Jun 23. Epub ahead of print
23. Bigot F, Castanon E, Baldini C, Hollebecque A, Carmona A, Postel-Vinay S, Angevin E, Armand JP, Ribrag V, Aspeslagh S, Varga A, Bahleda R, **Menis J**, Gazzah A, Michot JM, Marabelle A, Soria JC, Massard C.
Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
Eur J Cancer. 2017 Oct;84:212-218
24. Specenier PM, Remenar E, Buter J, Schrijvers DL, Bergamini C, Licitra LF, Awada A, Clement PM, Fortpied C, **Menis J**, Vermorken JB.
TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial.
Ann Oncol. 2017 Sep 1;28(9):2219-2224
25. Machiels JP, Bossi P, **Menis J**, Lia M, Fortpied C, Liu Y, Lhommel R, Lemort M, Schmitz S, Canevari S, De Cecco L, Guzzo M, Bianchi R, Quattrone P, Crippa F, Duprez T, Lalami Y, Quiriny M, de Saint Aubain N, Clement PM, Coropciuc R, Hauben E, Licitra LF.
Activity and safety of afatinib in a window pre-operative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN).
Ann Oncol. 2018 Jan 15. Epub ahead of print
26. Fasola G, **Menis J**, Follador A, De Carlo E, Valent F, Aresu G, De Pellegrin A, Giacomuzzi F, Iuri D, Lugatti E, Parisi G, Pacileo G.
Integrated care pathways in lung cancer: a quality improvement project.
Int J Technol Assess Health Care. 2018 Feb 6:1-7
27. Tryfonidis K, Papadaki C, Assele S, Lagoudaki E, **Menis J**, Koutsopoulos A, Trypaki M, Tsakalaki E, Sfakianaki M, Hasan B, Stathopoulos E, Georgoulas V, Souglakos J.
Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer.
Pharmacogenomics J. 2018 Feb 22. Epub ahead of print
28. Banna GL, Passiglia F, Colonese F, Canova S, Menis J, Addeo A, Russo A, Cortinovis DL.
Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection.
Crit Rev Oncol Hematol. 2018 Sep;129:27-39
29. Watson S, **Menis J**, Baldini C, Martin-Romano P, Michot JM, Hollebecque A, Armand JP, Massard C, Soria JC, Postel-Vinay S, Paoletti X.
Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?
Br J Cancer. 2018 Oct;119(8):937-939
30. Kataoka K, Kaider-Person O, Kasper B, Starlinger P, Caballero C, **Menis J**, Hendriks LE, Terada M, Collette L, Nakamura K, Lacombe D, Fukuda H.
Responding to the challenges of international collaborations between the east and the west - report of the first JCOG-EORTC symposium and a perspective from young JCOG and EORTC investigators.
Jpn J Clin Oncol. 2018 Nov 5. Epub ahead of print
31. *Reducing the burden: the economic and social costs of lung cancer in Italy.*
The Economist

